TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus
about
The nonantibiotic small molecule cyslabdan enhances the potency of β-lactams against MRSA by inhibiting pentaglycine interpeptide bridge synthesisNovelties in the field of parenteral cephem antibacterials since 1993.In vitro activity of cephalosporin RWJ-54428 (MC-02479) against multidrug-resistant gram-positive cocci.In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci.In vitro activity of the trinem sanfetrinem (GV104326) against gram-positive organisms.Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.Cephalosporins in clinical development.Osteoprotegerin Regulates Pancreatic β-Cell Homeostasis upon Microbial InvasionAnti-MRSA agents: under investigation, in the exploratory phase and clinically available.New β-lactam antibiotics and β-lactamase inhibitors.β-Lactams and β-Lactamase Inhibitors: An Overview.In vitro activities of novel trans-3,5-disubstituted pyrrolidinylthio-1beta-methylcarbapenems with potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.Therapeutic efficacy of BO-3482, a novel dithiocarbamate carbapenem, in mice infected with methicillin-resistant Staphylococcus aureus.In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem.Effects of tungstosilicate on strains of methicillin-resistant Staphylococcus aureus with unique resistant mechanisms.Novel anti-staphylococcal targets and compounds.
P2860
Q28484891-52075A92-3D3D-41F3-A939-080FD39AED66Q33218268-A7119873-C396-4C15-8358-D2D6F0142F0EQ34105195-1263A418-1D05-4E7E-95EA-04742605FDC4Q35124610-22CD0F28-C7CF-4DB5-BE54-298D5CC1A5B5Q35126947-310AF0B4-9D68-464F-848A-4C99AD2F4BB9Q35376362-D8A3FCA9-0873-4674-85FC-D868FF7CE92CQ35842532-4370A018-4EB1-4858-A540-3EAE82D356E7Q35890262-1CA72B69-3FB5-4826-919A-1017D9182DC4Q36233502-E18A8344-A9B5-4DD2-AF97-67E680702A34Q37788685-8F5B2554-8111-4157-BDE5-BDD2EFFDB4C2Q38872374-D49C85CB-76C4-40C7-B154-E337E944DBD6Q39472968-CE9B19A4-F20E-4BDA-944B-763F49C26919Q39785118-4FA6A1E1-6291-47E6-94B8-B9837C6B1C95Q42112589-82F7DEC4-8CEF-4C1E-9F02-FDCE6D106CFDQ44425721-8733BA5F-BE34-4E76-939A-5EE3E817ADA8Q53852773-502E2AFF-499F-48C4-A204-E3C2E4F15793
P2860
TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
TOC-39, a novel parenteral bro ...... esistant Staphylococcus aureus
@en
TOC-39, a novel parenteral bro ...... sistant Staphylococcus aureus.
@nl
type
label
TOC-39, a novel parenteral bro ...... esistant Staphylococcus aureus
@en
TOC-39, a novel parenteral bro ...... sistant Staphylococcus aureus.
@nl
prefLabel
TOC-39, a novel parenteral bro ...... esistant Staphylococcus aureus
@en
TOC-39, a novel parenteral bro ...... sistant Staphylococcus aureus.
@nl
P2093
P2860
P356
P1476
TOC-39, a novel parenteral bro ...... esistant Staphylococcus aureus
@en
P2093
P2860
P304
P356
10.1128/AAC.39.5.1120
P407
P577
1995-05-01T00:00:00Z